Global & Philippines Cancer Therapeutics Market to 2031

The cancer therapeutics market in the Philippines is witnessing growing demand, driven by the introduction of innovative treatments such as targeted therapies, immunotherapies, and biologics. Government efforts, notably through the National Integrated Cancer Control Act and the Philippine Health Insurance Corporation (PhilHealth), have significantly contributed to enhancing access to cancer care services and medications. Despite these advancements, challenges persist—particularly the high cost of therapies and limitations within the country’s healthcare infrastructure—which continue to restrict broader market expansion.

Cancer remains a leading cause of illness and death in the Philippines, with the Philippine Cancer Society reporting over 200,000 new diagnoses annually. In response to this growing burden, the oncology drug market—including chemotherapy, immunotherapy, targeted treatments, and biologics—has seen rapid growth. This transition toward more personalized and advanced therapies is transforming the way cancer is managed in the country.

Alongside the National Integrated Cancer Control Act, PhilHealth has been instrumental in easing the financial burden on patients by incorporating cancer treatment services into its benefit packages. Patients diagnosed with certain cancers can receive partial reimbursements for procedures such as chemotherapy, radiation, and surgery. PhilHealth’s cancer drug program has made vital treatments more accessible to individuals who may otherwise face significant financial barriers, especially in a healthcare system where out-of-pocket expenses are still widespread.